التفاصيل البيبلوغرافية
| العنوان: |
The Cost Effectiveness of Lisdexamfetamine Dimesylate for the Treatment of Binge Eating Disorder in the USA. |
| المؤلفون: |
Ágh, Tamás1 tamas.agh@syreon.eu, Pawaskar, Manjiri2, Nagy, Balázs, Lachaine, Jean3, Vokó, Zoltán |
| المصدر: |
Clinical Drug Investigation. Apr2016, Vol. 36 Issue 4, p305-312. 8p. |
| مصطلحات موضوعية: |
*COST effectiveness, *COMPULSIVE eating, *DRUG prices, *CLINICAL trials, *THERAPEUTICS |
| مصطلحات جغرافية: |
UNITED States |
| مستخلص: |
Background: Lisdexamfetamine dimesylate (LDX) demonstrated efficacy in terms of reduced binge eating days per week in adults with binge eating disorder (BED) in two randomized clinical trials (RCTs). Objective: The objective of this study was to evaluate the cost effectiveness of LDX versus no pharmacotherapy (NPT) in adults with BED from a USA healthcare payer's perspective. Study Design and Methods: A decision-analytic Markov cohort model was developed using 1-week cycles and a 52-week time horizon. Markov health states were defined based upon the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria of BED. Model parameter estimates were obtained from RCTs, a survey, and literature. The primary outcome was incremental cost-effectiveness ratio (ICER). The analysis assumed a 12-week course of treatment, based upon RCTs' treatment duration. One-way deterministic and probabilistic sensitivity analyses were conducted to assess the robustness of the results. Results: Patients on LDX therapy gained 0.006 quality-adjusted life years (QALY) compared to patients on the NPT arm, while the average total cost was US$175 higher for LDX therapy. The estimated ICER for LDX compared with NPT was US$27,618 per QALY, which was shown to be cost effective given a willingness-to-pay threshold of US$50,000. Conclusions: Treatment of BED with LDX showed increase in QALYs at an acceptable cost and is considered to be cost effective at the commonly used willingness-to-pay threshold in the USA. Based on the available evidence, the current model focused on short-term benefits only. There is a need to generate additional scientific evidence supporting long-term benefits of LDX therapy for BED. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
